226 related articles for article (PubMed ID: 22689668)
1. Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes.
Balduini A; Di Buduo CA; Malara A; Lecchi A; Rebuzzini P; Currao M; Pallotta I; Jakubowski JA; Cattaneo M
Haematologica; 2012 Nov; 97(11):1657-65. PubMed ID: 22689668
[TBL] [Abstract][Full Text] [Related]
2. Studies of the interaction of ticagrelor with the P2Y
Björquist A; Di Buduo CA; Femia EA; Storey RF; Becker RC; Balduini A; Nylander S; Cattaneo M
Thromb Haemost; 2016 Nov; 116(6):1079-1088. PubMed ID: 27605392
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
[TBL] [Abstract][Full Text] [Related]
5. Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling.
Tolhurst G; Vial C; Léon C; Gachet C; Evans RJ; Mahaut-Smith MP
Blood; 2005 Sep; 106(5):1644-51. PubMed ID: 15914557
[TBL] [Abstract][Full Text] [Related]
6. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
7. Mpl ligand increases P2Y1 receptor gene expression in megakaryocytes with no concomitant change in platelet response to ADP.
Hechler B; Toselli P; Ravanat C; Gachet C; Ravid K
Mol Pharmacol; 2001 Nov; 60(5):1112-20. PubMed ID: 11641440
[TBL] [Abstract][Full Text] [Related]
8. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
[TBL] [Abstract][Full Text] [Related]
9. A comparison of different regression models for the quantitative analysis of the combined effect of P2Y
Watala C; Wzorek J; Palma A; Boncler M
Thromb Res; 2022 Mar; 211():88-97. PubMed ID: 35134667
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome.
Strassel C; Eckly A; Léon C; Petitjean C; Freund M; Cazenave JP; Gachet C; Lanza F
Haematologica; 2009 Jun; 94(6):800-10. PubMed ID: 19377075
[TBL] [Abstract][Full Text] [Related]
11. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets.
Jagroop IA; Burnstock G; Mikhailidis DP
Platelets; 2003 Feb; 14(1):15-20. PubMed ID: 12623443
[TBL] [Abstract][Full Text] [Related]
12. P2Y₁ and P2Y₁₂ receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig.
Kylhammar D; Bune LT; Rådegran G
Eur J Appl Physiol; 2014 Sep; 114(9):1995-2006. PubMed ID: 24929904
[TBL] [Abstract][Full Text] [Related]
13. Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors.
Mamedova LK; Gao ZG; Jacobson KA
Biochem Pharmacol; 2006 Oct; 72(8):1031-41. PubMed ID: 16934758
[TBL] [Abstract][Full Text] [Related]
14. P2Y12 receptor: platelet thrombus formation and medical interventions.
Moheimani F; Jackson DE
Int J Hematol; 2012 Nov; 96(5):572-87. PubMed ID: 23054651
[TBL] [Abstract][Full Text] [Related]
15. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
16. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
[TBL] [Abstract][Full Text] [Related]
17. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Cattaneo M
Blood; 2011 Feb; 117(7):2102-12. PubMed ID: 20966167
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a PI3-kinase independent pathway in the regulation of Rap1b activation downstream of the P2Y12 receptor in platelets.
Dangelmaier C; Kunapuli SP
Platelets; 2022 Nov; 33(8):1301-1306. PubMed ID: 35514261
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.
Hardy AR; Jones ML; Mundell SJ; Poole AW
Blood; 2004 Sep; 104(6):1745-52. PubMed ID: 15187029
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function.
Suzuki T; Obara Y; Moriya T; Nakata H; Nakahata N
FEBS Lett; 2011 Dec; 585(24):3978-84. PubMed ID: 22079667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
